Ultime notizie per EBET (OTC:EBET) Azioni

EBET

EBET Inc is a technology company developing and operating platforms focused on esports and competitive gaming. It operates a licensed online gambling platform, which is an esports/sportsbook focused on bettors located in Asia and Latin America. It offers real-money betting on esports events from around the world in a secure environment. It accepts wagers on esports titles including Counter-Strike: GO, League of Legends, Dota 2, StarCraft 2, Rocket League, Rainbow Six, Warcraft 3, King of Glory, and FIFA, as well as professional sports including the NFL, NBA, MLB, soccer and more. The company's Brands Includes; Gogawi, Karamba, Griffon Casino, Generation VIP, and Others.

EBET Inc

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $15 to $8.

News

Price Target

Analyst Ratings

ZYXI

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $8

WIIM

SWK stock has given up its prior loss. Stanley Black & Decker shares were trading lower after the company lowered its FY25 adjusted EPS guidance.

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&amp;R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The transaction was completed on the terms previously disclosed. Sanofi has received total net cash proceeds of around €10 billion

Asset Sales

Sanofi Closed Sale Of 50% Stake In Opella To CD&R For €10B

Prominent short seller Jim Chanos criticized Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) robotaxi economic projections on Monday, calling the figures &#8220;ridiculous&#8221; and pointing to several overlooked cost factors.
What Happened: Chanos, responding to a Tesla investor&#8217;s profit calculations on X, highlighted that &#8220;roughly half of all ride-hailing miles are &#8216;dead&#8217; (non-revenue) miles.&#8221; He also noted commercial auto insurance costs &#8220;3- 4x personal auto insurance&#8221; at approximately &#8220;30-40 cents per mile,&#8221; with additional expenses for cleaning at $400 per month.
Chanos argued that the major cost for a Robotaxi fleet would be redundancy, safety, and monitoring, which the Massachusetts Institute of Technology has estimated could range from $0.05 to $2.35 per mile, depending on regulations. He also questioned the viability of Tesla&#8217;s projections by pointing out that the entire U.S. taxi and ridesharing market is expected to be valued at $50 billion to $75 billion in 2024.
When challenged about potential higher revenue, Chanos expressed doubt, citing consumers&#8217; ability to &#8220;operate their own vehicles at a marginal cost of 50-60 cents per mile&#8221; and noting that &#8220;commoditized service markets tend to converge revenues to marginal cost.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">These figures are, of course, ridiculous. First of all, roughly half of all ride-hailing miles are "dead" (non-revenue) miles. Second, commercial auto insurance is 3-4x personal auto insurance(10 cents per mile), or 30-40 cents per mile. Cleaning costs($400/month), etc. <a href="https://t.co/t5HJVooUsi">https://t.co/t5HJVooUsi</a>
&mdash; James Chanos (@RealJimChanos) <a href="https://twitter.com/RealJimChanos/status/1917029597574529280?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/25/04/45056962/bill-gates-says-hes-happier-as-a-billionaire-than-if-he-were-middle-class-you-dont-need-a-billionbut-freedom-from-worry-is-a-blessing">Bill Gates Says He&#8217;s Happier As A Billionaire Than If He Were Middle Class — &#8216;You Don&#8217;t Need A Billion…But Freedom From Worry Is A Blessing&#8217;</a>
Why It Matters: Tesla has been preparing for its limited robotaxi launch in Austin this June, with CEO Elon Musk announcing plans to deploy only 10-20 vehicles initially. The company has <a href="https://www.benzinga.com/tech/25/04/44972108/tesla-quietly-launched-robotaxi-service-for-employees-before-june-debut-now-reports-1500-completed-trips">already launched an employee-only autonomous ride-hailing service</a> in Austin and San Francisco, completing over 1,500 trips covering 15,000 miles.
Investor Gary Black recently described the upcoming launch as &#8220;an experiment&#8221; rather than a true market test, citing the limited deployment and &#8220;asymmetry of risks.&#8221; Former Waymo CEO John Krafcik has also questioned Tesla&#8217;s <a href="https://www.benzinga.com/markets/25/04/44979720/teslas-robotaxi-launch-in-june-will-likely-be-a-non-event-says-gary-black-this-isnt-really-a-test-market-its-an-experiment">readiness for autonomous taxi operations</a>.
Despite skepticism, Tesla has intensified testing efforts with approximately 300 drivers in Austin under &#8220;Project Rodeo,&#8221; while collaborating with local emergency services and developing its robotaxi app for the <a href="https://www.benzinga.com/tech/25/04/45028007/tesla-prepares-for-robotaxi-reveal-in-june-insiders-share-secrets">planned June 1 launch</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/45056965/dave-ramsey-says-doctors-and-lawyers-are-like-actors-notoriously-bad-with-money-just-because-you-make-a-lot-doesnt-mean-youre-winning">Dave Ramsey Says Doctors And Lawyers Are Like Actors, Notoriously Bad With Money — &#8216;Just Because You Make A Lot Doesn&#8217;t Mean You&#8217;re Winning&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Short Sellers

Markets

TSLA

Short Seller Jim Chanos Slams Tesla Robotaxi Economics As 'Ridiculous,' Citing Dead Miles, Insurance Costs And Cleaning Expenses

Leerink Partners analyst Puneet Souda downgrades Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) from Outperform to Market Perform and lowers the price target from $12 to $8.

Downgrades

QTRX

Leerink Partners Downgrades Quanterix to Market Perform, Lowers Price Target to $8

Earnings

GRMN

Garmin Q1 Gross Margin 57.6% vs 58.1% YoY

SPWR

SunPower Formerly Complete Solaria Reports Q1 Revenues Of $88.674M, Company Finished Q1 With $14M In Cash Vs. $13.3M In Q4

First Foundation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFWM#NYSE">FFWM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.03 by 200 percent. This is a 350 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $71.40 million which beat the analyst consensus estimate of $64.19 million by 11.24 percent. This is a 39.81 percent increase over sales of $51.07 million the same period last year.

Earnings Beats

FFWM

First Foundation Q1 Adj. EPS $0.09 Beats $0.03 Estimate, Sales $71.40M Beat $64.19M Estimate

Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 70.37 percent decrease over losses of $(0.27) per share from the same period last year.

Earnings Misses

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $2500 price target.

Reiteration

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $2500 Price Target

DTCK

Davis Commodities Forms Strategic Joint Venture With Malaysian Agri-Processor To Tap ASEAN FTA Benefits And Secure Key Market Access

EXTR

Extreme Networks Q3 2025 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $284.50M Beat $280.32M Estimate

USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company), today announced that it has entered into a securities purchase agreement with a new fundamental institutional investor to raise $75 million of equity capital via a private investment in public equity ("PIPE"). The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expenses.
Under the terms of the securities purchase agreement, the Company will issue, for an aggregate purchase price of $75 million, an aggregate of approximately 8.55 million shares of common stock (the Issued Shares), pre-funded warrants to purchase an aggregate of approximately 2.16 million shares of common stock (the shares underlying the Pre-Funded Warrants, together with the Issued Shares, "the Aggregate Shares") and warrants (the PIPE Warrants) to purchase shares of common stock, in an amount equal to 100% of the Aggregate Shares at a strike price of $7.00 per share, with an expiry date of 6-years from the issue date of the PIPE Warrants. The Shares and the PIPE Warrant Shares are entitled to customary resale registration rights.
 &nbsp;

USAR

USA Rare Earth Enters Into Securities Purchase Agreement With New Fundamental Institutional Investor To Raise $75M Of Equity Capital Via PIPE

TLRY

Tilray Brands' 10 Barrel Brewing Unveils NA Apocalypse IPA, Offering Bold, Hop-Driven Flavor Without The Alcohol

ETSY

Etsy Q1 2025 Adj. EPS $0.46 Misses $0.49 Estimate, Sales $651.18M Beat $642.67M Estimate

Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. This is a 51.85 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $2.35 billion which beat the analyst consensus estimate of $2.30 billion by 2.33 percent. This is a 14.00 percent decrease over sales of $2.73 billion the same period last year.

Dana Q1 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $2.35B Beat $2.30B Estimate

Leerink Partners analyst Puneet Souda downgrades NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) from Outperform to Market Perform and lowers the price target from $25 to $9.

Leerink Partners Downgrades NeoGenomics to Market Perform, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Yi Chen reiterates LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and maintains $14 price target.

LFMD

HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $14 Price Target

Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) affirms FY2025 Adj EPS guidance from $4.40-$4.60 to $4.40-$4.60 vs $4.49 analyst estimate..

Guidance

Spire Affirms FY2025 Adj EPS Guidance of $4.40-$4.60 vs $4.49 Est

<ul>
<li>Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026</li>
<li>Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events</li>
<li>Avexitide has been previously evaluated in five post-bariatric hypoglycemia (PBH) clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events</li>
<li>The Company continues to expect cash runway through the end of 2026</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amylyx.com%2F&amp;esheet=54246224&amp;newsitemid=20250429337166&amp;lan=en-US&amp;anchor=Amylyx+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=4a42d2ccab20c0ba32567d801f80a9bc">Amylyx Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) ("Amylyx" or the "Company") today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH).

Amplify YieldShares Oil Hedged MLP Income ETF

Comments

EBET

Notizie

Ultime notizie per EBET (OTC:EBET) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO